Anti-tumor effect of a histone deacetylase inhibitor on canine malignant melanoma

Abstract

Canine malignant melanoma (CMM) is a highly aggressive tumor with limited treatment options. Histone deacetylase (HDAC) inhibitors have shown promise in cancer therapy by modulating gene expression. In this study, we investigated the anti-tumor effect of an HDAC inhibitor, vorinostat, on CMM cell lines. Vorinostat significantly suppressed cell proliferation through apoptosis and G0/G1 phase cell cycle arrest in vitro. These findings suggest that vorinostat might serve as a potential therapeutic agent for dogs with CMM, providing a basis for further in vivo studies.